CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage biotech Emyria Ltd to study five novel MDMA-inspired drug candidates for severe neuropsychiatric conditions. Emyria and its partner, the University of Western Australia, will initially screen five novel MDMA analogs with PsychoGenic’s computer vision and AI-based testing platform. The organizations expect the alliance to inform and…